XK469R in Treating Patients With Refractory Hematologic Cancer

You may be eligible if

• Diagnosis of 1 of the following relapsed or refractory hematologic malignancies for which all potentially curative therapy options have been exhausted:
• * Acute myeloid leukemia\* (AML) (non-M3)
• * Acute lymphoblastic leukemia\*
• * Myelodysplastic syndromes\*, including the following:
• * Refractory anemia with excess blasts (RAEB)
• * RAEB in transformation
• * Chronic myelomonocytic leukemia in transformation\* (CMML-t) with ≥ 10% peripheral blood/bone marrow blasts
• * Chronic myelogenous leukemia in blast crisis\* (CML-BC)
• * Chronic lymphocytic leukemia
• * Rai stage III-IV
• * Failed prior fludarabine-based therapy and ≥ 1 other therapy
• * Fludarabine failure defined as failure to achieve partial response or complete response (CR) to at least 1 fludarabine-containing regimen; disease progression while on fludarabine; or disease progression within 6 months of response to fludarabine
• Not a candidate for autologous or allogeneic stem cell transplantation (SCT)
• Patients with previously untreated AML, MDS, or CMML-t who are considered inappropriate candidates for, or refused, standard induction chemotherapy due to older age or concurrent medical conditions are eligible
• No known CNS disease
• Performance status - ECOG 0-2
• See Disease Characteristics
• Bilirubin \< 1.5 times upper limit of normal (ULN)
• AST and ALT \< 5 times ULN
• Creatinine \< 1.5 times ULN
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to XK469R
• No other uncontrolled illness
• HIV-positive patients allowed provided CD4 counts are normal with no AIDS-defining disease
• No prior allogeneic SCT
• No concurrent prophylactic hematopoietic colony-stimulating factors
• More than 7 days since prior cytotoxic chemotherapy (except hydroxyurea)
• More than 7 days since prior radiotherapy
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No other concurrent anti-leukemia agents
• No other concurrent anticancer therapy